NCT03493932View on ClinicalTrials.gov

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

April 21, 2023

Study Completion Date

June 27, 2023

Conditions
Glioblastoma
Interventions
DRUG

Nivolumab

OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.

DRUG

BMS-986016

Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb

Trial Locations (2)

20892

National Institutes of Health Clinical Center, Bethesda

30322

Emory University, Atlanta

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | Biotech Hunter | Biotech Hunter